Calcitriol Related Published Studies
Well-designed clinical trials related to Calcitriol
Intravenous calcitriol versus paricalcitol in haemodialysis patients with severe secondary hyperparathyroidism. [2009.08]
Comparison of oral falecalcitriol and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism: a randomized, crossover trial. [2009.06]
Comparison of intermittent intravenous and oral calcitriol in the treatment of secondary hyperparathyroidism in chronic hemodialysis patients: a meta-analysis of randomized controlled trials. [2009.03]
The efficacy and safety of calcitriol and/or Caltrate D in elderly Chinese women with low bone mass. [2009.03]
Calcium balance during calcitriol and paricalcitol administration in healthy humans. [2008.03]
Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel. [2008.01.15]
Oral calcitriol versus oral alfacalcidol for the treatment of secondary hyperparathyroidism in patients receiving hemodialysis: a randomized, crossover trial. [2008.01]
Systematic review of the benefits and harms of calcitriol and alfacalcidol for fractures and falls. [2008]
Comparison of cutaneous tolerance and efficacy of calcitriol 3 mug g(-1) ointment and tacrolimus 0.3 mg g(-1) ointment in chronic plaque psoriasis involving facial or genitofemoral areas: a double-blind, randomized controlled trial. [2007.11]
Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. [2007.02.20]
Effects of a combined alendronate and calcitriol agent (Maxmarvil(R)) on bone metabolism in Korean postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study. [2006.12]
Comparison of the effects of daily and intermittent-dose calcitriol on serum parathyroid hormone and ionized calcium concentrations in normal cats and cats with chronic renal failure. [2006.11]
High dose calcitriol may reduce thrombosis in cancer patients. [2006.11]
Calcitriol does not prevent bone loss in patients with asthma receiving corticosteroid therapy: a double-blind placebo-controlled trial. [2006.10]
Calcitriol in the treatment of prostate cancer. [2006.07]
Attempted randomized controlled trial of pamidronate versus calcium and calcitriol supplements for management of steroid-induced osteoporosis in children and adolescents. [2005.11]
Comparison of the efficacy of an oral calcitriol pulse or intravenous 22-oxacalcitriol therapies in chronic hemodialysis patients. [2005.09]
Randomized study on oral administration of calcitriol to prevent symptomatic hypocalcemia after total thyroidectomy. [2005.09]
ASCENT: the androgen-independent prostate cancer study of calcitriol enhancing taxotere. [2005.09]
Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysis. [2005.05]
Rationale for the development and current status of calcitriol in androgen-independent prostate cancer. [2005.02]
Well-designed clinical trials possibly related to Calcitriol
Experimental approach to optimize phytate phosphorus utilization by broiler chickens by addition of supplements. [2009.08]
Quality of life in patients with scalp psoriasis treated with calcipotriol/betamethasone dipropionate scalp formulation: a randomized controlled trial. [2009.08]
Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial. [2009.07]
Vitamin D supplementation enhances the beneficial effects of weight loss on cardiovascular disease risk markers. [2009.05]
[Effects of Xianling Gubao capsules for the treatment of bone loss induced by glucocorticoid] [2009.03]
1alpha,25-Dihydroxyvitamin D(3) to skew intratumoral levels of immune inhibitory CD34(+) progenitor cells into dendritic cells. [2009.02]
Comparing clobetasol propionate 0.05% spray to calcipotriene 0.005% betamethasone dipropionate 0.064% ointment for the treatment of moderate to severe plaque psoriasis. [2009.01]
A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. [2009.01]
Inter-species differences in sensitivity to the calcemic activity of the novel 1,25-dihydroxyvitamin D3 analog BXL746. [2008.12]
A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. [2008.09]
Effect of teriparatide on early bone loss after kidney transplantation. [2008.09]
Short and long-term variations in serum calciotropic hormones after a single very large dose of ergocalciferol (vitamin d2) or cholecalciferol (vitamin d3) in the elderly. [2008.08]
FokI variant of vitamin D receptor gene and factors related to atherosclerosis associated with ossification of the posterior longitudinal ligament of the spine: a multi-hospital case-control study. [2008.07.15]
FokI variant of vitamin D receptor gene and factors related to atherosclerosis associated with ossification of the posterior longitudinal ligament of the spine: a multi-hospital case-control study. [2008.07.15]
Treatment of reduced bone density with ibandronate in dialysis patients. [2008.07]
C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial. [2008.06.01]
Cutaneous pharmacokinetics of topically applied maxacalcitol ointment and lotion. [2008.06]
C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial. [2008.06]
Topical treatment of mild to moderate plaque psoriasis with 0.3% tacrolimus gel and 0.5% tacrolimus cream: the effect on SUM score, epidermal proliferation, keratinization, T-cell subsets and HLA-DR expression. [2008.04]
Association of vitamin D receptor gene 3'-variants with Hashimoto's thyroiditis in the Croatian population. [2008.04]
Calcium Homeostasis During Magnesium Treatment in Aneurysmal Subarachnoid Hemorrhage. [2008.03.04]
High-calcium mineral water as a calcium supplementing measure for post-thyroidectomy hypocalcemia. [2008.03]
Clinical effect of vitamin D3 analogues is not inactivated by subsequent UV exposure. [2008.02]
A comparison of twice-daily calcipotriol ointment with once-daily short-contact dithranol cream therapy: quality-of-life outcomes of a randomized controlled trial of supervised treatment of psoriasis in a day-care setting. [2008.02]
Effect of 1,25(OH)2-vitamin D on bone mass in children with acute lymphoblastic leukemia. [2008.01]
Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis. [2008]
Calcium homeostasis during magnesium treatment in aneurysmal subarachnoid hemorrhage. [2008]
A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long-term management of scalp psoriasis. [2008]
Calcipotriol plus betamethasone dipropionate scalp formulation is effective and well tolerated in the treatment of scalp psoriasis: a phase II study. [2008]
Preliminary findings: 25(OH)D levels and PTH are indicators of rapid bone accrual in pubertal children. [2007.10]
Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis. [2007.06]
Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial. [2007.05]
Smoothing the mosaic subclinical melanoderma by calcipotriol. [2007.05]
Combination of 308-nm xenon chloride excimer laser and topical calcipotriol in vitiligo. [2007.04]
ED-71, a new active vitamin D3, increases bone mineral density regardless of serum 25(OH)D levels in osteoporotic subjects. [2007.03]
A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. [2007.03]
[Therapeutic agents for disorders of bone and calcium metabolism. ED-71] [2007.01]
Efficacy, safety and quality of life of calcipotriol/betamethasone dipropionate (Dovobet((R))) versus calcipotriol (Daivonex((R))) in the treatment of psoriasis vulgaris: A randomized, multicentre, clinical trial. [2007]
Effect of angiotensin converting enzyme inhibitors on 1.25-(OH)2 D levels of hypertensive patients. Relationship with ACE polymorphisms. [2006.12]
Effect of topical vitamin D analogue on in vivo contact sensitization. [2006.10]
A randomized, multicenter study of calcipotriene ointment and clobetasol propionate foam in the sequential treatment of localized plaque-type psoriasis: short- and long-term outcomes. [2006.10]
Pamidronate reduces bone loss after allogeneic stem cell transplantation. [2006.10]
A comparison of twice-daily calcipotriol ointment with once-daily short-contact dithranol cream therapy: a randomized controlled trial of supervised treatment of psoriasis vulgaris in a day-care setting. [2006.10]
1% pimecrolimus, 0.005% calcipotriol, and 0.1% betamethasone in the treatment of intertriginous psoriasis: a double-blind, randomized controlled study. [2006.09]
Retrospective assessment of PASI 50 and PASI 75 attainment with a calcipotriol/betamethasone dipropionate ointment. [2006.08]
Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. [2006.08]
Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. [2006.08]
Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up. [2006.08]
A randomized trial of intermittent versus continuous oral alfacalcidol treatment of hyperparathyroidism in end-stage renal disease. [2006.06]
A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treatment of psoriasis vulgaris. [2006.06]
Effects of 25-hydroxyvitamin D3 and manipulated dietary cation-anion difference on the tenderness of beef from cull native Korean cows. [2006.06]
Narrow-band ultraviolet B as monotherapy and in combination with topical calcipotriol in the treatment of vitiligo. [2006.05]
The effects of calcipotriol and methylprednisolone aseponate on bcl-2, p53 and ki-67 expression in psoriasis. [2006.05]
Estrogen receptor alpha gene polymorphisms are associated with changes in bone remodeling markers and treatment response to estrogen. [2006.03.20]
Discontinuing antiresorptive therapy one year after cardiac transplantation: effect on bone density and bone turnover. [2006.03.15]
Effect of topical calcipotriol, betamethasone dipropionate and their combination in the treatment of localized vitiligo. [2006.03]
[New horizons of ED-71 (vitamin D analog)] [2006.01]
BXL628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial. [2006.01]
Use of calcipotriene cream (Dovonex cream) following acute treatment of psoriasis vulgaris with the calcipotriene/betamethasone dipropionate two-compound product (Taclonex): a randomized, parallel-group clinical trial. [2006]
0.3% Tacrolimus gel and 0.5% Tacrolimus cream show efficacy in mild to moderate plaque psoriasis: Results of a randomized, open-label, observer-blinded study. [2006]
A comparison of dosing regimens of paricalcitol capsule for the treatment of secondary hyperparathyroidism in CKD stages 3 and 4. [2006]
Efficacy results of a 52-week, randomised, double-blind, safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet/Dovobet/Taclonex) in the treatment of psoriasis vulgaris. [2006]
The effects of lanthanum carbonate and calcium carbonate on bone abnormalities in patients with end-stage renal disease. [2005.12]
Effects of 3 diets with various calcium contents on 24-h energy expenditure, fat oxidation, and adipose tissue message RNA expression of lipid metabolism-related proteins. [2005.12]
Short-term effects on bone turnover of replacing milk with cola beverages: a 10-day interventional study in young men. [2005.12]
A new active vitamin D, ED-71, increases bone mass in osteoporotic patients under vitamin D supplementation: a randomized, double-blind, placebo-controlled clinical trial. [2005.09]
Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols. [2005.08]
BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial. [2005.08]
'Atrophic telogen effluvium' from cytotoxic drugs and a randomized controlled trial to investigate the possible protective effect of pretreatment with a topical vitamin D analogue in humans. [2005.07]
Vitamin D receptor Fok1 polymorphisms affect calcium absorption, kinetics, and bone mineralization rates during puberty. [2005.06]
Dairy augmentation of total and central fat loss in obese subjects. [2005.04]
Clobetasol propionate shampoo 0.05% and calcipotriol solution 0.005%: a randomized comparison of efficacy and safety in subjects with scalp psoriasis. [2005.02]
Control of parathyroid function in patients with a short history of hemodialysis. [2005.02]
Recombinant growth hormone therapy for X-linked hypophosphatemia in children. [2005.01.25]
Efficacy and local safety of a calcipotriol/ betamethasone dipropionate ointment in elderly patients with psoriasis vulgaris. [2005.01]
Psoriasis vulgaris: once-versus twice-daily application of calcipotriol cream. [2005]
Calcipotriol monotherapy versus calcipotriol plus UVA1 versus calcipotriol plus narrow-band UVB in the treatment of psoriasis. [2005]
Bone mineral density, body height, and vitamin D receptor gene polymorphism in middle-aged men. [2005]
Cost-effectiveness of once-daily treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol in the treatment of Psoriasis vulgaris. [2005]
Comparison of tazarotene 0.1% gel plus petrolatum once daily versus calcipotriol 0.005% ointment twice daily in the treatment of plaque psoriasis. [2005]
|
